PL401408A1 - Genistein-nicotinamide monohydrate co-crystal and a method for preparing genistein-nicotinamide monohydrate co-crystal - Google Patents

Genistein-nicotinamide monohydrate co-crystal and a method for preparing genistein-nicotinamide monohydrate co-crystal

Info

Publication number
PL401408A1
PL401408A1 PL401408A PL40140812A PL401408A1 PL 401408 A1 PL401408 A1 PL 401408A1 PL 401408 A PL401408 A PL 401408A PL 40140812 A PL40140812 A PL 40140812A PL 401408 A1 PL401408 A1 PL 401408A1
Authority
PL
Poland
Prior art keywords
genistein
nicotinamide
crystal
monohydrate
amount
Prior art date
Application number
PL401408A
Other languages
Polish (pl)
Inventor
Michal Sowa
Ewa Matczak-Jon
Katarzyna Ślepokura
Original Assignee
Politechnika Wroclawska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Politechnika Wroclawska filed Critical Politechnika Wroclawska
Priority to PL401408A priority Critical patent/PL401408A1/en
Publication of PL401408A1 publication Critical patent/PL401408A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

Wynalazek dotyczy kokrysztalu monohydratu genisteina-nikotynamid o wzorze 3 i jego zastosowania w przemysle farmaceutycznym i/lub kosmetycznym. Wynalazek ujawnia równiez sposób otrzymywania kokrysztalu monohydratu genisteina - nikotynamid o wzorze 3 charakteryzujacy sie tym, ze genisteine w ilosci od 25 do 50 mg oraz nikotynamid w ilosci od 150 do 300 mg rozpuszcza sie w od 5 do 10 ml, etanolu i metanalu, po czym calosc miesza sie, przesacza sie, a nastepnie pozostawia sie do powolnego odparowania w temperaturze pokojowej, a po 2 do 4 tygodni zbiera sie krysztaly. W innej metodzie sposobu otrzymywania kokrysztalu monohydratu genisteina - nikotynamid o wzorze 3, umieszcza sie genisteine i nikotynamid w ilosci stechiometrycznej 1:1 w stalowym naczyniu mlyna kulowego, po czym dodaje sie wode lub mieszanine acetonitryl z woda w ilosci 50 ?l na kazde 50 mg genisteiny, poddaje sie mieleniu przez 5-45 minut, przy czestosci drgan 50-60 Hz. Tak otrzymany material mikrokrystaliczny suszy sie w temperaturze pokojowej przez czas od 12 do 24 godzin i poddaje analizie na dyfraktometrze proszkowym.The invention relates to the genistein-nicotinamide monohydrate co-crystal of formula 3 and its use in the pharmaceutical and / or cosmetics industry. The invention also discloses a method for the preparation of the co-crystal monohydrate genistein - nicotinamide of formula 3 characterized in that genisteine in the amount of 25 to 50 mg and nicotinamide in the amount of 150 to 300 mg are dissolved in 5 to 10 ml, ethanol and methanal, after which the whole is mixed, filtered and then allowed to evaporate slowly at room temperature, and after 2 to 4 weeks the crystals collect. In another method of obtaining the co-crystal of monohydrate genistein - nicotinamide of formula 3, place genisteine and nicotinamide in a stoichiometric amount of 1: 1 in a steel ball mill vessel, after which water or a mixture of acetonitrile with water in the amount of 50 ml for each 50 mg is added genistein, milled for 5-45 minutes, with a vibration frequency of 50-60 Hz. The microcrystalline material thus obtained is dried at room temperature for 12 to 24 hours and analyzed on a powder diffractometer.

PL401408A 2012-10-30 2012-10-30 Genistein-nicotinamide monohydrate co-crystal and a method for preparing genistein-nicotinamide monohydrate co-crystal PL401408A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL401408A PL401408A1 (en) 2012-10-30 2012-10-30 Genistein-nicotinamide monohydrate co-crystal and a method for preparing genistein-nicotinamide monohydrate co-crystal

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL401408A PL401408A1 (en) 2012-10-30 2012-10-30 Genistein-nicotinamide monohydrate co-crystal and a method for preparing genistein-nicotinamide monohydrate co-crystal

Publications (1)

Publication Number Publication Date
PL401408A1 true PL401408A1 (en) 2013-06-10

Family

ID=48539640

Family Applications (1)

Application Number Title Priority Date Filing Date
PL401408A PL401408A1 (en) 2012-10-30 2012-10-30 Genistein-nicotinamide monohydrate co-crystal and a method for preparing genistein-nicotinamide monohydrate co-crystal

Country Status (1)

Country Link
PL (1) PL401408A1 (en)

Similar Documents

Publication Publication Date Title
MA33838B1 (en) Amorphous and crystalline form of the metrons of Keynes 112638 as a cloxylsramide synthetase inhibitor
UA112317C2 (en) 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists
PH12012501800A1 (en) 2,3 dihydro- 1h - inden- 1 - yl -2,7 -diazaspirol [ 3.5 ] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
BR112012026257A2 (en) solid forms of 3- (6- (1- (2-, 2-difluorbenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic acid
CO6531445A2 (en) BENCIMIDAZOL-IMIDAZOL DERIVATIVES
UA116774C2 (en) Serine/threonine kinase inhibitors
NO20073791L (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
PH12015501585A1 (en) Manufacturing process for pyrimidine derivatives
MX2021002261A (en) Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-m ethyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)p henyl)benzamide and its mono hydrochloride salt.
WO2013177534A3 (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
PL402710A1 (en) Pharmaceutical compositions comprising imatinib or a pharmaceutically acceptable salt thereof and methods for their preparation
MX2015007853A (en) Diazole amides.
MX2015012403A (en) Crystalline forms of tyrosine kinase inhibitors and their salts.
NZ630816A (en) N-(2-(cyclic amine)ethyl)benzamide derivatives as p2x7 inhibitors
EA201170300A1 (en) CRYSTAL FORMS OF PYRIDINE DERIVATIVE
IN2014DN06122A (en)
NO20076161L (en) Methods for preparing 4-biphenylazetidin-2-ones
NZ720879A (en) Indazole compounds as 5-ht4 receptor agonists
PL401412A1 (en) Hemietanolat fisetin-nicotinamide co-crystal and a method for preparing fisetin-nicotinamide co-crystal
PL401409A1 (en) Myricetin-piracetam co-crystal and process for the preparation thereof
PL401410A1 (en) Myricetin-caffeine co-crystal and a method for preparing mricetin-caffeine co-crystal
PL401413A1 (en) Fisetin-isonicotinamide co-crystal and a method for preparing fisetin-isonicotinamide co-crystal
PL401414A1 (en) Baicalein-nicotinamide co-crystal and a method for preparing baicalein-nicotinamide co-crystal
PL400213A1 (en) Imidazo [1,2-b] pyridazine-6-amine derivatives as JAK-2 kinase inhibitors
PL405443A1 (en) Fisetin-caffeine cocrystal and a method for obtaining fisetin-caffeine cocrystal

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)